$0.68
-0.02 (-3.21%)
Open$0.72
Previous Close$0.70
Day High$0.75
Day Low$0.66
52W High$1.45
52W Low$0.65
Volume—
Avg Volume118.3K
Market Cap25.37M
P/E Ratio—
EPS$-0.24
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,709.2% upside
Current
$0.68
$0.68
Target
$32.64
$32.64
$20.70
$32.64 avg
$34.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.43M | 3.03M | 4.58M |
| Net Income | -5,705,101 | -4,529,855 | -1,151,647 |
| Profit Margin | -166.2% | -157.9% | -25.2% |
| EBITDA | -5,713,740 | -4,788,754 | -1,556,423 |
| Free Cash Flow | — | — | -1,101,967 |
| Rev Growth | +13.4% | +13.4% | +24.2% |
| Debt/Equity | 2.01 | 2.01 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |